Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGT-309 for Identifying Cancerous Colorectal Lesions During Colonoscopy
NCT06034197Phase 1Terminated
- Start
- Feb 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abenacianine in colorectal cancer (CRC). Primary endpoints: Safety Profile of VGT309 at 18 days and Feasibility of VGT-309 at 18 days. Started Feb 2024; status: terminated.
02
Drugs
abenacianine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06034197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06034197.